Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
The approval of Fyarro was based on data from the phase 2 AMPECT study.
Sarcoma News
SARCOMA CANCER ADVISOR
Sarcoma News
Long-Term Safety Data Support Benefit-Risk Profile of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
NBTXR3 plus radiotherapy did not negatively affect quality of life or long-term morbidity in locally advanced soft tissue sarcoma.
Lack of Radiosensitivity Associated With Poor Outcomes in Myxoid Liposarcomas
Researchers found that lack of radiosensitivity was associated with poor outcomes in patients with myxoid liposarcomas.
Radiotherapy May Improve Outcomes in Extremity Soft Tissue Sarcoma
Neoadjuvant and adjuvant radiotherapy were associated with a reduced risk of local recurrence.
Immune Checkpoint Inhibitors May Offer Benefit in Recurrent Chordoma
Most patients included in the retrospective analysis received ICI treatment as their first line of therapy (59%).
Regimen May Be Beneficial as Palliative Care for Children, Young Adults With Solid Tumors
Stable disease was observed in 51.3% of patients.
Lower Household Income May Increase Risk of Amputation in Extremity Bone Sarcoma
Amputation was significantly more likely in patients with household incomes below $75,000 per year.
High Rate of Complications Reported in Sarcoma Patients With COVID-19
The hospitalization rate was 49%, and 16% of patients died.
Survival Benefit Persists With Fourth-Line Ripretinib in GIST
The 24-month overall survival rate was 42.8%.
Nab-Sirolimus Deemed ‘Important New Treatment Option’ for Malignant Perivascular Epithelioid Cell Tumors
The overall response rate was 39%.
‘Best Survival to Date’ in Phase 3 Trial of Ewing Sarcoma
The 5-year overall survival rate was 87%.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Genomic Sequencing in Pediatric Cancer: For Every Patient at Every Relapse
More than one-third of tumors sequenced carried a high mutation burden.
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma
Young adults were more likely to receive chemotherapy.
Triplet Deemed New Standard Care for Relapsed or Refractory Rhabdomyosarcoma
Adding temozolomide to vincristine and irinotecan improved survival.
Avapritinib Does Not Improve PFS in Advanced Gastrointestinal Stromal Tumors
The VOYAGER study did not meet its primary endpoint.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
CMB305 Vaccine Demonstrates Activity But Doesn’t Improve Survival in Soft-Tissue Sarcomas
CMB305 increased antibody responses and NY-ESO-1-specific T-cell responses.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...